Home › Research › Costs and economics
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Ross EL, Weinberg MS, Arnold SE. JAMA Neurology, 2022-03-28
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients to estimate whether aducanumab and donanemab were reasonably priced for the health benefit they provide. At the prices assumed in the model, both drugs cost far more per year of good-quality life gained than standard cost-effectiveness benchmarks, with aducanumab performing especially poorly and donanemab needing a much lower price to be considered good value.
What this study adds
Evidence grade: Moderate
Aducanumab performed especially poorly and donanemab needed a much lower price to be considered good value. Its stated limit: A modelling study based on simulated disease progression and extrapolated trial data rather than observed long-term outcomes; published before donanemab's actual FDA approval and pricing, so it used an assumed hypothetical price rather than the drug's real launch price.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ross, E. L., Weinberg, M. S., & Arnold, S. E. (2022). Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2022.0315
Vancouver
Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. JAMA Neurology. 2022. doi:10.1001/jamaneurol.2022.0315. PMID: 35344024.
BibTeX
@article{ross2022-b0c356d3,
author = {Ross, E. L. and Weinberg, M. S. and Arnold, S. E.},
title = {{Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US}},
journal = {JAMA Neurology},
year = {2022},
doi = {10.1001/jamaneurol.2022.0315},
pmid = {35344024},
url = {https://doi.org/10.1001/jamaneurol.2022.0315}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Modeled ICER for aducanumab was $981,000 per QALY gained (health care sector perspective)
- Modeled ICER for donanemab was $193,000 per QALY gained (health care sector perspective)
- To meet a $150,000/QALY willingness-to-pay threshold, aducanumab's price would need to drop to about $2,000-$3,000/year and donanemab's to about $17,000-$22,000/year
- Donanemab produced substantially more modeled lifetime QALYs (0.408) than aducanumab (0.133) in the base case
Why it matters
Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients and found that at the prices assumed in the model, both aducanumab and donanemab cost far more per year of good-quality life gained than standard cost-effectiveness benchmarks. Aducanumab performed especially poorly and donanemab needed a much lower price to be considered good value.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designmodelling
- Effect sizeBase-case ICER of $981,000/QALY (health care sector) for aducanumab and $193,000/QALY (health care sector) for donanemab; to reach a $150,000/QALY threshold, annual price would need to fall to about $2,000-$3,000 for aducanumab and $17,000-$22,000 for donanemab
- Evidence strengthModerate
Limitations
A modelling study based on simulated disease progression and extrapolated trial data rather than observed long-term outcomes; published before donanemab's actual FDA approval and pricing, so it used an assumed hypothetical price rather than the drug's real launch price.
How this study scored 52/100
Published in a leading specialty journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 32 of the 62 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 3 / 12 | A computer model rather than new measurements |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35344024) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 32 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 62 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
14 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Costs and economics from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.